Washington hosted the inaugural meeting of the US-India Drug Policy Executive Working Group on January 20-21, marking a pivotal step in bilateral efforts to combat the worldwide drug crisis. The Indian Ministry of External Affairs highlighted the discussions, emphasizing firm commitments to a safer, healthier future for both nations.
Led by Sarah Carter, Director of the White House Office of National Drug Control Policy (ONDCP), the session underscored the shared vision of US President Donald Trump and Indian Prime Minister Narendra Modi to bolster security cooperation and eradicate narco-terrorism. Carter stressed that the drug epidemic now ranks as a top national security priority, with this working group leveraging bilateral ties to protect families while supporting legitimate industries.
India’s Ambassador to the US, Vinay Kwatra, affirmed New Delhi’s top priority on tackling drug trafficking and precursor chemical diversions, balancing robust enforcement with facilitation of legitimate trade. Under the guidance of ONDCP Acting Deputy Director Debbie Seguin and India’s Narcotics Control Bureau Deputy Director General Monika Ashish Batra, delegations from both sides forged concrete outcomes to advance counter-narcotics collaboration.
The talks spotlighted the importance of a whole-of-government approach, streamlining inter-agency and inter-governmental efforts to secure pharmaceutical supply chains in line with national regulations. Recent joint operations dismantling illegal drug trafficking networks were hailed as successes, building on years of expanding US-India security ties that now prominently feature anti-drug initiatives against cross-border syndicates.
This partnership signals a new era in global drug control, promising sustained action against an escalating threat that transcends borders and jeopardizes public health and safety worldwide.